High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 3, 2015, Pages 631-639

  Colbert, Lauren E ^a,b,c   Fisher, Sarah B ^a,b   Balci, Serdar ^a,b   Saka, Burcu ^a,b   Chen, Zhengjia ^b   Kim, Sungjin ^b   El Rayes, Bassel F ^a,b   Adsay, N Volkan ^a,b   Maithel, Shishir K ^a,b   Landry, Jerome C ^a,b   Curran, Walter J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY;

CONFIDENCE INTERVAL; HYPOXIA INDUCIBLE FACTOR 1-ALPHA; IMMUNOHISTOCHEMICAL STAINING; METHODS AND MATERIALS; MULTIVARIATE LOGISTIC REGRESSIONS; NEOADJUVANT THERAPY; PANCREATIC ADENOCARCINOMA; UNIVARIATE ANALYSIS;

LOGISTIC REGRESSION;

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FOLLOW UP; GASTROINTESTINAL RADIOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PATHOLOGIST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADENOCARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; REGRESSION ANALYSIS; SECONDARY; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84923314757     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.11.004     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. S.C. Mayo, M.M. Gilson, and J.M. Herman Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy J Am Coll Surg 214 2012 33 45
3. D. Moghanaki, R. Mick, and E.E. Furth Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma JOP 12 2011 438 444
4. T. Kitada, S. Seki, and H. Sakaguchi Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma Histopathology 43 2003 550 555
5. P. Birner, M. Schindl, and A. Obermair Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy Clin Cancer Res 7 2001 1661 1668
6. P. Birner, M. Schindl, and A. Obermair Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer Cancer Res 60 2000 4693 4696
7. K. Ogawa, I. Chiba, and T. Morioka Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy Anticancer Res 31 2011 2351 2359
8. T.R. Spivak-Kroizman, G. Hostetter, and R. Posner Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer Cancer Res 73 2013 3235 3247
9. S.B. Fisher, S.H. Patel, and P. Bagci An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment Cancer 119 2013 445 453
10. S.K. Maithel, I. Coban, and P.J. Kneuertz Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection Ann Surg Oncol 18 2011 2699 2705
11. L.E. Colbert, S.B. Fisher, and C.W. Hardy Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma Cancer 119 2013 3148 3155
12. O. Basturk, R. Singh, and E. Kaygusuz GLUT-1 expression in pancreatic neoplasia: Implications in pathogenesis, diagnosis, and prognosis Pancreas 40 2011 187 192
13. S.B. Fisher, S.H. Patel, and P. Bagci An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment Cancer 119 2013 445 453
14. D. Ansari, A. Rosendahl, and J. Elebro Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer Br J Surg 98 2011 1041 1055
15. N.B. Jamieson, C.R. Carter, and C.J. McKay Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis Clin Cancer Res 17 2011 3316 3331
16. C.A. Iacobuzio-Donahue, B. Fu, and S. Yachida DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
17. J.M. Winter, L.H. Tang, and D.S. Klimstra Failure patterns in resected pancreas adenocarcinoma: Lack of predicted benefit to SMAD4 expression Ann Surg 258 2013 331 335
18. T. Ide, Y. Kitajima, and A. Miyoshi The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling Ann Surg Oncol 14 2007 2600 2607
19. A.C. Hoffmann, R. Mori, and D. Vallbohmer High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF Neoplasia 10 2008 674 679
20. H.C. Sun, Z.J. Qiu, and J. Liu Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis Int J Oncol 30 2007 1359 1367
21. G.W. Huang, L.Y. Yang, and W.Q. Lu Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival World J Gastroenterol 11 2005 1705 1708
22. Z.F. Yang, R.T. Poon, and J. To The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma Cancer Res 64 2004 5496 5503
23. H. Wei, F. Li, and P. Fu Effects of the silencing of hypoxia-inducible factor-1 alpha on metastasis of pancreatic cancer Eur Rev Med Pharmacol Sci 17 2013 436 446
24. D.L. Schwartz, J.A. Bankson, and R. Lemos Jr. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer Mol Cancer Ther 9 2010 2057 2067
25. D.L. Schwartz, G. Powis, and A. Thitai-Kumar The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects Mol Cancer Ther 8 2009 947 958
26. A. Couvelard, D. O'Toole, and R. Leek Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas Histopathology 46 2005 668 676
27. J.P. Neoptolemos, J.A. Dunn, and D.D. Stocken Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial Lancet 358 2001 1576 1585
28. D. Schellenberg, J. Kim, and C. Christman-Skieller Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 81 2011 181 188
29. S.H. Oh, J.K. Woo, and Q. Jin Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha Int J Cancer 122 2008 5 14
30. K. Kasuya, A. Tsuchida, and Y. Nagakawa Hypoxia-inducible factor-1alpha expression and gemcitabine chemotherapy for pancreatic cancer Oncol Rep 26 2011 1399 1406
31. L.M. McShane, D.G. Altman, and W. Sauerbrei Identification of clinically useful cancer prognostic factors: What are we missing? J Natl Cancer Inst 97 2005 1023 1025
32. L.M. McShane, D.G. Altman, and W. Sauerbrei Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
33. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Urol 2 2005 416 422
34. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Oncol 2 2005 416 422
35. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391
36. L.M. McShane, D.G. Altman, and W. Sauerbrei Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
37. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumour MARKer prognostic studies (REMARK) Eur J Cancer 41 2005 1690 1696
38. L.M. McShane, and D.F. Hayes Publication of tumor marker research results: The necessity for complete and transparent reporting J Clin Oncol 30 2012 4223 4232